Natasha Pillay Smiley, DO
- Pediatric Neuro-Oncologist, Cancer and Blood Diseases Institute
- Associate Professor, UC Department of Pediatrics
- natasha.pillay-smiley@cchmc.org
- Board Certified
About
Biography
I completed my medical training at Chicago College of Osteopathic Medicine and Pediatrics Residency at Advocate Children's Lutheran General Hospital in the Chicago area. I went on to the Pediatric Hematology/Oncology/Stem Cell Transplant Fellowship at Nationwide Children's Hospital in Columbus, OH before returning to Chicago for a Pediatric Neuro-Oncology Fellowship and the start of my career at Northwestern University/Ann & Robert H. Lurie Children's Hospital.
Interests
Pediatric CNS disease; CNS specific survivorship; CNS specific cancer predisposition including NF-1 and NF-2
Services and Specialties
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
A multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy. Neuro-Oncology Practice. 2026; 13(4):807-815.
ID #890 Multi-institutional analysis of outcomes of pediatric patients with high-risk (HR) WNT-subtype medulloblastoma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.384.
ID #854 Updated findings from a phase 1 study of savolitinib in recurrent, progressive, or refractory medulloblastoma (MB), high-grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG), and central nervous system (CNS) tumors harboring MET aberrations: A Pediatric Brain Tumor Consortium Trial: PBTC-049. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.360.
ID #761 Feasibility study of hypofractionated radiotherapy in the setting of recurrent diffuse intrinsic pontine glioma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.320.
ID #651 A phase 1/2 and surgical Pediatric Brain Tumor Consortium (PBTC) study evaluating the casein kinase 2 (CK2) inhibitor CX-4945 (silmitasertib sodium) in children and adults with recurrent sonic hedgehog (SHH) medulloblastoma (MB): PBTC-053. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.260.
ID #634 Case Series of the Use of Trihexyphenidyl for Tremors in Pediatric Brain Tumors. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.247.
ID #476 Increased Prevalence of Optic Nerve Hypoplasia in Neurofibromatosis Type 1. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.170.
ID #472 Burnout Among Advanced Practice Providers in a Pediatric Oncology Setting. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.168.
ID #1028 A Retrospective Review Characterizing the Toxicities, Outcomes, and Molecular Characteristics of Adolescent and Young Adult Patients with Medulloblastoma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.457.
ID #1002 Hematologic Toxicity during Proton Radiation: a Review of Weekly CBC Results at a Single Center. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.440.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey